Global life sciences executive search firm, the RSA Group, has published a new study analysing the performance of biotechnology boards, CEOs and chairs from both Europe and the US, from an investor viewpoint, demonstrating that European companies are outperforming US ones.
Europe vs USA
When measuring average market capitalisation, RSA Group found that US-based companies were leaders — $3.1 billion vs $727 million. However, this measure alone is not enough for overall performance analysis.